Search results
5 lip 2024 · Memantine (brand name Namenda) is an oral NMDA blocker that may be used to treat moderate to severe dementia in people with Alzheimer’s disease. Memantine is an NMDA (N-methyl-D-aspartate) blocker that works by binding to NMDA-receptor-operated cation channels and blocking their effect.
6 cze 2023 · Memantine is a noncompetitive moderate‐affinity strong voltage‐dependent N‐methyl‐D‐aspartate receptor antagonist. It has been used to treat Alzheimer's disease (AD) since 1989. In 2018, it became the second most commonly used drug for the treatment of dementia in the world.
Memantine is used to treat the symptoms of Alzheimer's disease (AD; a brain disease that slowly destroys the memory and the ability to think, learn, communicate and handle daily activities). Memantine is in a class of medications called NMDA receptor antagonists.
13 mar 2018 · Memantine (MEM), an antagonist of extrasynaptic NMDAR, is currently used for the treatment of AD jointly with acetylcholinesterase inhibitors. It has been demonstrated that MEM preferentially prevents the excessive continuous extrasynaptic NMDAR disease activation and therefore prevents neuronal cell death induced by excitotoxicity without ...
2 mar 2007 · Memantine (1-amino–3, 5-dimethyladamanantate) is an adamantane derivative that blocks the NMDA receptor-associated ion channel similar to magnesium by binding to or near the magnesium-binding site (Lipton 2004).
Memantine is a medicine for dementia. It is used to treat memory loss which is one of the main symptoms of dementia. It is also used to treat the symptoms of: Alzheimer's disease; dementia with Lewy bodies; mixed dementia – when you have more than one type of dementia; corticobasal degeneration (CBD) Memantine does not work for everyone.
DrugBank Accession Number. DB01043. Background. Initially approved by the FDA in 2013, memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist used in the management of Alzheimer's Disease (AD).
